---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-093512"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2026-08-25T20:05:29+00:00"
generated_at: "2026-08-25T20:06:28.646487+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vyome Q2 2026 net loss $0.7M; advances VT-1953 FDA plan, in-licenses JAK inhibitors

## Summary
- Net loss of $720K ($0.10/share) for Q2 2026; cash $7.9M vs $5.0M at Dec 31, 2025.
- Received FDA written response on VT-1953 pivotal study strategy; plans Type C meeting.
- In-licensed two selective JAK inhibitor assets from Impetis Biosciences for autoimmune conditions.
- Granted Chinese patent for VB-1953 topical gel formulation and therapeutic acne claims.
- Phase 2 VT-1953 data showed significant malodor/pain reductions with no treatment-emergent AEs.

## SEC filing metadata
- accession: 0001213900-26-093512
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2026-08-25T20:05:29+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000121390026093512/0001213900-26-093512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000121390026093512/ea0303228-8k_vyome.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-093512
- JSON: https://secwatch.observer/filing/0001213900-26-093512.json
- Plain text: https://secwatch.observer/filing/0001213900-26-093512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.